LIVE TUMOR BANKING PERSONALIZED TUMORGRAFT PERSONALIZED VACCINE PERSONALIZED ONCOLOGY PANEL PHYSICIAN FAQ CASE PRESENTATIONS CLINICAL REFERENCES GUEST LOGIN
Physician Brochure
Read news on recent Champions' breakthroughs in cancer treatment
SCHEDULE A
SCIENTIFIC PRESENTATION
EMAIL US:
Empower@PersonalizedCancerTreatment.com
CALL TOLL FREE:
866.790.1447
SCIENTIFIC PRESENTATION
EMAIL US:
Empower@PersonalizedCancerTreatment.com
CALL TOLL FREE:
866.790.1447
CLINICAL REFERENCES
Champions offers specialists a powerful new tool in their therapeutic armamentarium — a more precise and individualized approach to cancer treatment — one that may optimize the treatment plan’s potential for success while maximizing a patient’s most precious resource — time. Simply put, this means if therapeutic success is not achieved initially, Champions’ technology may provide more time for new drugs and treatments to develop for the benefit of the patient.
To learn more about the benefits of Champions' Personalized Oncology Services,
Schedule a Scientific Presentation.
(All following links are downloadable PDF files)
- Assessment of Celecoxib Pharmacodynamics in Pancreatic Cancer
Jimeno A et al. Mol Cancer Ther 2006, 5 (12): 3240-7 - An In Vivo Platform for Translational Drug Development in Pancreatic Cancer
Rubio Viqueira B et al. Clin Cancer Res 2006, 12(15) - Development of Two Novel Benzoylphenylurea Sulfur Analogues and Evidence that the Microtubuleassociated Protein Tau is Predictive of Their Activity in Pancreatic Cancer
Jimeno A et al. Mol Cancer Ther 2007, 6(5):1509–16 - Dual Mitogen-Activated Protein Kinase and Epidermal Growth Factor Receptor Inhibition in Biliary and Pancreatic Cancer
Jimeno A et al. Mol Cancer Ther 2007, 6(3):1079–88 - Towards Personalized Medicine: Establishment and In Vivo Characterization of a Low Passage Tumor Xenograft Predictive of Clinical Response
Lowell W et al. 2007 AACR Int Conf Mol Diag Can Ther Dev - Optimizing the Development of Targeted Agents in Pancreatic Cancer: Tumor Fine-Needle Aspiration Biopsy as a Platform for Novel Prospective Ex Vivo Drug Sensitivity Assays
Rubio Viqueira B et al. Mol Cancer Ther 2007, 6(2):515–23 - In Vitro and In Vivo Assays and Models: Poster Presentations - Proffered Abstracts
Wick M et al. 2008 AACR Int Conf Mol Diag Can Ther Dev - Coordinated Epidermal Growth Factor Receptor Pathway Gene Overexpression Predicts Epidermal Growth Factor Receptor Inhibitor Sensitivity in Pancreatic Cancer
Jimeno A et al. Cancer Res 2008, 68(8): 2841–9 - Evaluation of the Novel Mitotic Modulator ON 01910.Na in Pancreatic Cancer and Preclinical Development of an Ex Vivo Predictive Assay
Jimeno A et al. Oncogene 2008, 1–9 - A Direct Pancreatic Cancer Xenograft Model as a Platform for Cancer Stem Cell Therapeutic Development
Jimeno A et al. Mol Cancer Ther 2009, 8(2):OF1–5 - Efficacy and Pharmacodynamic Effects of Bosutinib (SKI-606), a Src/Abl Inhibitor, in Freshly Generated Human Pancreas Cancer Xenografts
Messersmith et al. Mol Cancer Ther 2009;8(6). June 2009 - Antitumor Effects and Biomarkers of Activity of AZD0530,a Src Inhibitor, in Pancreatic Cancer
Clin Cancer Res 2009;4139 15(12) June 15, 2009
